Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.. Additionally we are shipping Elongation Factor RNA Polymerase II Proteins (3) and Elongation Factor RNA Polymerase II Kits (1) and many more products for this protein.
Showing 10 out of 93 products:
Dog (Canine) Polyclonal ELL Primary Antibody for WB - ABIN2779278
Wang, Xu, Han, Shi, Luo, Jiang, Lin, Huang, Xia, Guan: High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. in Cancer 2007
Show all 2 Pubmed References
ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 (show THBS1 Antibodies) regulation
The results indicate that p53 (show TP53 Antibodies) interferes with the interaction between ELL/EAF and ICE1 and represses transcription of small nuclear RNA genes by Pol II (show 0 Antibodies).
This work reveals a previously unrecognized function for ELL as an E3 ubiquitin ligase (show MUL1 Antibodies) for c-Myc (show MYC Antibodies) and a potential tumour suppressor.
The Tax (show CNTN2 Antibodies) oncogene (show RAB1A Antibodies) enhances ELL incorporation into p300 (show EP300 Antibodies) and P-TEFb (show CCNT1 Antibodies) containing protein complexes to activate transcription.
eleven-nineteen lysine-rich leukemia protein enhanced E2F1 (show E2F1 Antibodies) deacetylation via recruitment of histone deacetylase 1 (show HDAC1 Antibodies)
ELL is an essential player for RNA Pol II (show 0 Antibodies) restart during cellular DNA damage response.
Studies indicate that the super elongation complex (SEC) consisting of ELL, P-TEFb (CDK9 (show CDK9 Antibodies)) and MLL (show MLL Antibodies) required for rapid transcriptional induction in the presence or absence of paused RNA polymerase II (Pol II (show 0 Antibodies)).
ELL has an early and essential role during rapid high-amplitude gene expression that is required for both Pol II (show 0 Antibodies) pause site entry and release
Our findings suggest that ELL and HIF-1alpha (show HIF1A Antibodies) are binding partners and can modulate the functions of each other in hypoxia.
In the Acute Myeloid Leukemia (show BCL11A Antibodies) patients, detected MLL (show MLL Antibodies) rearrangements consisting of MLL (show MLL Antibodies)/AF6 (show MLLT4 Antibodies), MLL (show MLL Antibodies)/AF9 (show MLLT3 Antibodies), MLL (show MLL Antibodies)/AF17 , MLL (show MLL Antibodies)/ELL and MLL (show MLL Antibodies) partial tandem duplication. MLL (show MLL Antibodies) rearrangement include chromosome translocation and partial tandem duplication.
Elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.
RNA polymerase II elongation factor ELL
, ELL gene (11-19 lysine-rich leukemia gene)
, eleven-nineteen lysine-rich leukemia protein
, protein phosphatase 1, regulatory subunit 68
, RNA POLYMERASE II ELONGATION FACTOR ELL (ELEVEN-NINETEEN LYSINE-RICH LEUKEMIA PROTEIN)